Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC
NCT06694129
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer
ROS1 Gene Rearrangement
Resistance
Targeted Therapy
Interventions
DRUG:
Entrectinib
Sponsor
National Cancer Center, China